FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213332912> ?p ?o ?g. }

• W4213332912 abstract "Many studies have reported high efficacy and safety of artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) when administered under direct observation in Cameroon. There is paucity of data to support their continuous use in home-based treatment of uncomplicated Plasmodium falciparum malaria in Cameroon. Hence, this study aimed to assess the effectiveness and safety of AS-AQ versus AL for home-based treatment of uncomplicated P. falciparum malaria among children 6-120 months in Yaoundé, Cameroon.A two-arm, open-label, randomized, controlled trial comparing the equivalence of AS-AQ (experimental group) and AL (control group) was carried out from May 2019 to April 2020 at two secondary hospitals in Yaoundé. Participants were randomized to receive either AS-AQ or AL. After the first dose, antimalarial drugs were given at home, rather than under direct observation by a study staff. The conventional on-treatment and post-treatment laboratory and clinical evaluations were not done until day 3 of the full antimalarial treatment course. The evaluation of effectiveness was mainly based on per protocol polymerase chain reaction adjusted adequate clinical and parasitological response (PP PCR adjusted ACPR) on day 28 post-treatment. Safety was based on assessment of adverse events (AEs) and severe adverse events (SAEs) from day 1 to day 28.A total of 242 children were randomized to receive AS-AQ (n = 114) and AL (n = 128). The PP PCR adjusted day 28 cure rates were [AS-AQ = 96.9% (95% CI, 91.2-99.4) versus AL = 95.5% (95% CI, 89.9-98.5), P = 0.797]. Expected mild to moderate adverse events were reported in both arms [AS-AQ = 83 (84.7%) versus AL = 99 (86.1%), P = 0.774]. The most common adverse events included: transient changes of hematologic indices and fever.This study demonstrated that AS-AQ and AL are effective and safe for home management of malaria in Yaoundé. The evidence from this study supports the parallel use of the two drugs in routine practice. However, the findings from this study do not describe the likely duration of antimalarial effectiveness in holoendemic areas where multiple courses of treatment might be required.This study is a randomized controlled trial and it was retrospectively registered on 23/09/2020 at ClinicalTrials.gov with registration number NCT04565184." @default.
• W4213332912 created "2022-02-24" @default.
• W4213332912 creator A5004218960 @default.
• W4213332912 creator A5013524950 @default.
• W4213332912 creator A5014204959 @default.
• W4213332912 creator A5016318683 @default.
• W4213332912 creator A5020653913 @default.
• W4213332912 creator A5023957519 @default.
• W4213332912 creator A5030491812 @default.
• W4213332912 creator A5034331307 @default.
• W4213332912 creator A5039722694 @default.
• W4213332912 creator A5041990558 @default.
• W4213332912 creator A5046327673 @default.
• W4213332912 creator A5048931250 @default.
• W4213332912 creator A5052170450 @default.
• W4213332912 creator A5056093448 @default.
• W4213332912 creator A5056171683 @default.
• W4213332912 creator A5062640961 @default.
• W4213332912 creator A5068770175 @default.
• W4213332912 creator A5069083679 @default.
• W4213332912 creator A5071004075 @default.
• W4213332912 creator A5072044956 @default.
• W4213332912 creator A5072828100 @default.
• W4213332912 creator A5073597588 @default.
• W4213332912 creator A5074103607 @default.
• W4213332912 creator A5077442227 @default.
• W4213332912 creator A5078378257 @default.
• W4213332912 creator A5081917715 @default.
• W4213332912 creator A5085513349 @default.
• W4213332912 creator A5085522877 @default.
• W4213332912 creator A5086369459 @default.
• W4213332912 creator A5090453188 @default.
• W4213332912 date "2022-02-21" @default.
• W4213332912 modified "2023-10-10" @default.
• W4213332912 title "Effectiveness and safety of artesunate–amodiaquine versus artemether–lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6–120 months in Yaoundé, Cameroon: a randomized trial" @default.
• W4213332912 cites W1599689831 @default.
• W4213332912 cites W1970272857 @default.
• W4213332912 cites W1973985245 @default.
• W4213332912 cites W1977660784 @default.
• W4213332912 cites W1987975938 @default.
• W4213332912 cites W2011052290 @default.
• W4213332912 cites W2030481162 @default.
• W4213332912 cites W2051456573 @default.
• W4213332912 cites W2064021654 @default.
• W4213332912 cites W2097116672 @default.
• W4213332912 cites W2098872233 @default.
• W4213332912 cites W2106806905 @default.
• W4213332912 cites W2109191053 @default.
• W4213332912 cites W2109688696 @default.
• W4213332912 cites W2115137370 @default.
• W4213332912 cites W2116368541 @default.
• W4213332912 cites W2122389877 @default.
• W4213332912 cites W2123618955 @default.
• W4213332912 cites W2124634096 @default.
• W4213332912 cites W2128573330 @default.
• W4213332912 cites W2136283984 @default.
• W4213332912 cites W2136945880 @default.
• W4213332912 cites W2145633183 @default.
• W4213332912 cites W2157360098 @default.
• W4213332912 cites W2158873553 @default.
• W4213332912 cites W2162280767 @default.
• W4213332912 cites W2168468717 @default.
• W4213332912 cites W2278775782 @default.
• W4213332912 cites W2278977493 @default.
• W4213332912 cites W2315311689 @default.
• W4213332912 cites W2402230524 @default.
• W4213332912 cites W2411245132 @default.
• W4213332912 cites W2415685063 @default.
• W4213332912 cites W2467259677 @default.
• W4213332912 cites W2471559361 @default.
• W4213332912 cites W2704477461 @default.
• W4213332912 cites W2733245723 @default.
• W4213332912 cites W2794868066 @default.
• W4213332912 cites W2796055571 @default.
• W4213332912 cites W2922347673 @default.
• W4213332912 cites W2923208923 @default.
• W4213332912 cites W2952468349 @default.
• W4213332912 cites W2981340699 @default.
• W4213332912 cites W3001008900 @default.
• W4213332912 cites W3007190031 @default.
• W4213332912 cites W3007844511 @default.
• W4213332912 cites W3011559098 @default.
• W4213332912 cites W3012441801 @default.
• W4213332912 cites W3027255350 @default.
• W4213332912 cites W3031413726 @default.
• W4213332912 cites W3046809066 @default.
• W4213332912 cites W3094170938 @default.
• W4213332912 cites W3094333000 @default.
• W4213332912 cites W3154986366 @default.
• W4213332912 cites W3200040377 @default.
• W4213332912 cites W3033857641 @default.
• W4213332912 doi "https://doi.org/10.1186/s12879-022-07101-2" @default.
• W4213332912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35189818" @default.
• W4213332912 hasPublicationYear "2022" @default.
• W4213332912 type Work @default.
• W4213332912 citedByCount "4" @default.
• W4213332912 countsByYear W42133329122023 @default.
• W4213332912 crossrefType "journal-article" @default.
• W4213332912 hasAuthorship W4213332912A5004218960 @default.
• W4213332912 hasAuthorship W4213332912A5013524950 @default.

• next